Hashimoto H. Zur Kenntniss der lymphomatösen Veränderung der Schilddrüse (Struma lymphomatosa). Arch. Lin. Chir. 1912; 97: 219–48.
Boldyreva Yu.V., Lebedev I.A., Kruchinin E.V., Alekberov R.I., Tarasov D.O., Tyapkin A.V. et al. A unified approach to the management of patients with autoimmune thyroiditis (literature review). Ural’skiy meditsinskiy zhurnal. 2019; 7(175): 110-3. (in Russian)
Rozhko V.A. The current state of the problem of autoimmune thyroiditis. Problemy zdorov’ya i ekologii. 2019; 2(60): 4-13. (in Russian)
Mattozzi S., Sabater L., Escudero D., Arino H., Armangue T., Simabukuro M. et al. Hashimoto encephalopathy in the 21st century. Neurology. 2020; 94(2): 217-24. https://doi.org/10.1212/WNL.0000000000008785
Caturegli P., De R.A., Rose N.R. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun. Rev. 2014; 13(4-5): 391–7. https://doi.org/10.1016/j.autrev.2014.01.007
Latina A., Gullo D., Trimarchi F., Benvenga S. Hashimoto’s thyroiditis: similar and dissimilar characteristics in neighboring areas. Possible implications for the epidemiology of thyroid cancer. PLoS One. 2013; 8: e55450.
Tomer Y., Davies T.F. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocrine Reviews. 2003; 24(5): 694-717. https://doi.org/10.1210/er.2002-0030
Simmonds M.J. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat. Rev. Endocrinol. 2013; 9(5): 277–87. https://doi.org/10.1038/nrendo.2013.56
Tomer Y., Hasham A., Davies T.F., Stefan M., Concepcion E., Keddache M. et al. Fine mapping of loci linked to autoimmune thyroid disease identifies novel susceptibility genes. J. Clin. Endocrinol. Metab. 2013; 98(1): 144–52. https://doi.org/10.1210/jc.2012-2408
Hodge S.E., Ban Y., Strug L.J., Greenberg D.A., Davies T.F., Concepcion E.S. et al. Possible interaction between HLA-DRbeta1 and thyroglobulin variants in Graves’ disease. Thyroid. 2006; 16(4): 351-5. https://doi.org/10.1089/thy.2006.16.351
Shalaby S.M., Mackawy A.M.H., Atef D.M., Atef R.M., Saeed J. Promoter methylation and expression of intercellular adhesion molecule 1 gene in blood of autoimmune thyroiditis patients. Molecular biology reports. 2019; 46: 5345-53. https://doi.org/10.1007/
s11033-019-04990-6
McLeod D.S., Caturegli P., Cooper D.S., Matos P.G., Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA. 2014; 311(15): 1563–5. https://doi.org/10.1001/jama.2013.285606
Huang C.Y., Chang T.Y., Chu C.C., Lo F.S., Ting W.H., Lin C.H. et al. The HLA-B gene and Hashimoto disease in Han Chinese children: a case-control and family-based study. Tissue Antigens. 2012; 80(5): 431-6. https://doi.org/10.1111/tan.12003
Ueda S., Oryoji D., Yamamoto K., Noh J.Y., Okamura K., Noda M. et al. Identification of independent susceptible and protective HLA alleles in Japanese autoimmune thyroid disease and their epistasis. J. Clin. Endocrinol. Metab. 2014; 99(2): 379–83.
Bernecker C., Ostapczuk M., Vordenbaumen S., Ehlers M., Thiel A., Schinner S. et al. HLA-A2 phenotype may be protective against Graves’ disease but not against Hashimoto’s thyroiditis in Caucasians. Horm. Metab. Res. 2013; 45(1): 74–7. https://doi.org/10.1055/
s-0032-1323704
Antonelli A., Ferrari S.M., Corrado A., Di Domenicantonio A., Fallahi P. Autoimmune thyroid disorders. Autoimmunity Reviews. 2015; 14(2): 174-80. https://doi.org/10.1016/j.autrev.2014.10.016
Sharipova Z.F., Farkhutdinova L.M., Kilsenbaeva F.A. Dependence of the function of the thyroid gland on the severity of the autoimmune component. Meditsinskaya immunologiya. 2006; 8(2-3): 239. (in Russian)
Kadricheva S.G., Savchenko A.A. Prediction of the level of autoantibodies in patients with autoimmune diseases of the thyroid gland using the levels of metabolic enzymes of blood lymphocytes. Meditsinskaya immunologiya. 2001; 3(2): 182. (in Russian)
Witte T.T., Hartung K., Sachse C., Matthias T., Fricke M., Deicher H. et al. IgM anti-ds DNA antibodies in systemic lupus erythematosus: negative assotiation with nephritis. SLE Study Group. Rheumatology international. 1998; 18(3): 85-91.
Weetman A.P. The immunopathogenesis of chronic autoimmune thyroiditis one century after hashimoto. Eur. Thyroid. J. 2013; 1(4): 243–50.
Orgiazzi J. Thyroid autoimmunity. Presse medicale. 2012; 41(12): 611-25. https://doi.org/10.1016/j.lpm.2012.10.002
Dubska M., Banga J.P., Plochocka D., Hoser G., Kemp E.H., Gardas A. et al. Structural insights into autoreactive determinants in thyroid peroxidase composed of discontinuous and multiple key contact amino acid residues contributing to epitopes recognized by
patients’ autoantibodies. Endocrinology. 2006; 147(12): 5995-6003. https://doi.org/10.1210/en.2006-0912
Ajjan R.A., Kemp E.H., Waterman E.A., Watson P.F., Endo T., Onaya T. et al. Detection of binding and blocking autoantibodies to the human sodium-iodide symporter in patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 2000; 85(5): 2020–7.
https://doi.org/10.1210/jcem.85.5.6526
Kakudo K., Li Y., Hirokawa M., Ozaki T. Diagnosis of Hashimoto’s thyroiditis and IgG4-related sclerosing disease. Pathol. Int. 2011; 61(4): 175–83. https://doi.org/10.1111/j.1440-1827.2011.02661.x
Kemp E.H., Sandhu H.K., Watson P.F., Weetman A.P. Low frequency of pendrin autoantibodies detected using a radioligand binding assay in patients with autoimmune thyroid disease. J. Clin. Endorinol. Metab. 2013; 98(2): 309–13. https://doi.org/10.1210/jc.2012-3683
Chiovato L.L., Latrofa F., Braverman L.E., Pacini F., Cappezone M., Masserini L. et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann. Intern. Med. 2003; 2(139): 346-51. https://doi.org/10.7326/
0003-4819-139-5_Part_1-200309020-00010
Bresson D., Rebuffat S., Peraldi-Roux S. Localization of the immunodominant region on human thyroid peroxidase in autoimmune thyroid disease: an update. J. Autoimmune Dis. 2005; 2(1): 2. https://doi.org/10.1186/1740-2557-2-2
Bijl M., Horst G., Limburg P.C., Kallenberg C.G. Anti-CD3-induced and anti-Fas-induced apoptosis in systemic lupus erythematosus (SLE). Clin. Exp. Immunol. 2001; 123(1): 127-32. https://doi.org/10.1046/j.1365-2249.2001.01418.x
Tsao B.P., Cantor R.M., Kalinian K.C. Evidence for linkage of a candidate chromosome I region to human systemic lupus erythematosus. J. Clin. Invest. 1997; 99: 725-31.
Lacroix-Desmazes S.S., Bayry J., Misra N., Horn M.P., Villard S., Pashov A. et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. New Engl. J. Med. 2002; 346(9): 662-7. https://doi.org/10.1056/NEJMoa011979
Pisetsky D.S. Specificity and immunochemical properties of antibodies to bacterial DNA. Methods. 1997; 11(1): 55-61. https://doi.org/10.1006/meth.1996.0387
Pedro A.B., Romaldini J.H., Americo C., Takei K. Association of circulating antibodies against double-stranded and single- stranded DNA with thyroid autoantibodies in Graves’ disease and Hashimoto’s thyroiditis patients. Exp. Clin. Endocrinol. Diabetes. 2006; 114(
1): 35-8. https://doi.org/10.1055/s-2005-873005
Kozyr A.V., Kolesnikov A.V., Aleksandrova E.S., Sashchenko L.P., Gnuchhev N.V., Favorov P.V. et al. Novel functional activities of anti-DNA autoantibodies from sera of patient with lymphoproliferative and autoimmune desease. Appl. Biochem. Biotechnol. 1998; 75(1):
45-61. https://doi.org/10.1007/BF02787708
Nevinsky G.A., Kanyshkova T.G., Semenov D.V., Buneva V.N. Catalytically active antibodies and their possible biological function. Vestnik RAMN. 2001; 2: 38-45. (in Russian)
Breusov A.A., Galvita A.V., Benzo E.S. Comparison of the activity level of polyclonal DNA hydrolyzing antibodies in patients with autoimmune thyroiditis and non-toxic nodular goiter. Russian Journal of Immunology. 2001; 6: 17-28. (in Russian)
Zorina V.N., Trofimenko N.A., Arkhipova S.V., Zorina R.M., Zorin N.A. Complexes of alpha-2-macroglobulin with antibodies of class G, plasmin and their relationship with other factors of humoral immunity in the development of rheumatoid arthritis. Meditsinskaya
immunologiya. 2005; 7(5-6): 557-62. (in Russian)
Zorin N.A., Zorina V.N. Macroglobulin signaling system. Biomeditsinskaya khimiya, 2012; 58(4): 400-10. https://doi.org/10.18097/pbmc20125804400 (in Russian)
Fiedorczyk M., Klimiuk P.A., Sierakowski S., Gindzienska-Sieskiewicz E., Chwiecko J. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. The Journal of Rheumatology. 2006; 33(8): 1523-9.
Urbaniak-Kujda D., Kapelko-Slowik K., Prajs I., Dybko J., Wolowiec D., Biernat M. et al. Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma.
Hematology. 2016; 21(1): 26-33. https://doi.org/10.1179/1607845415Y.0000000043
Tsai C.C., Wu S.B., Chang P.C., Wei Y.H. Alteration of connective tissue growth factor (CTGF) expression in orbital fibroblasts from patients with Graves’ ophthalmopathy. PLoS One. 2015; 10(11): e0143514. https://doi.org/10.1371/journal.pone.0143514
Myśliwiec J., Adamczyk M., Pawłowski P., Nikołajuk A, Górska M. Serum gelatinases (MMP-2 and MMP-9) and VCAM-1 as a guideline in a therapeutic approach in Graves ophthalmopathy. Endokrynol. Pol. 2007; 58(2): 105–9.
